The News
Exercising harder may matter more than total exercise time
A large prospective study suggests that how hard you move may matter more than how long, and that the answer differs depending on which disease you're trying to prevent.
The Try, the Fall, and the Law Nobody Enforced.
A shoulder dislocation during a try is an avoidable injury. The Smiley Sporty Doc explains the anatomy behind this preventable sport injury and why it needs to stop.
Time to Taper: The Science Behind Why Less Running Makes You Faster
A deep dive into the science of the taper, why 'taper tantrums' happen, and how to reveal your peak performance.
The ACSM Now Recommends Power Training for All Adults. Is the Fitness Industry Ready?
The ACSM has just recommended power training for healthy adults for the first time. A sports medicine physician explains why this is the most clinically significant update in the guidelines, the real injury risk it carries, and whether the fitness industry is ready to deliver it safely.
What is a bone stress injury?
What they are, how they are diagnosed, who is at risk, and what return to sport looks like, based on the published evidence.
The Scan Was Fine. It Was Just the Wrong Leg.
Real Madrid’s alleged MRI mix-up involving Kylian Mbappé is more than a football story. A sports medicine physician unpacks the science of wrong-side imaging errors, why they happen, why they’re underreported, and why the most underrated safety mechanism in medicine is you.
Resistance Training Guidelines Updated for First Time in 17 Years
For the first time in 17 years, the ACSM has rewritten the rules on resistance training. The verdict: consistency beats complexity, and you need less than you think.
Ozempic and Tendon Rupture: Should You Be Worried?
A new study links Ozempic and GLP-1 drugs to higher tendon rupture risk. But the headlines are missing crucial context. A sports medicine physician looks at the data from a different angle.
GLP-1 drugs linked to higher tendon rupture rates in people with obesity and type 2 diabetes
ⓘ Reported by Medscape • Research presented by Jad Lawand et al., AAOS Annual Meeting, March 2026 A large retrospective cohort study drawing on electronic health records from over 70 US healthcare organisations has found that GLP-1 receptor agonist (GLP-1 RA) use, such as Ozempic or Wegovy, is associated with